Background
==========

Exogenous stem cell therapy has shown benefits for treating peripheral arterial disease patients, who are not amenable for conventional revascularization therapy. Previously, we have demonstrated the ability of imaging-visible cell microencapsulation to overcome the challenges of poor cell retention/survival and difficulties with monitoring cell delivery success. However, *in vivo* cell viability cannot be assessed noninvasively. Here, we investigate the potential of PET-MRI tracking of ^19^F MRI-visible microencapsulated human mesenchymal stem cells (hMSCs) labeled with triple-fusion (TF) reporter gene in non-immunosuppressed rabbits.

Methods
=======

Bone marrow-derived hMSCs were stably transfected with a lentiviral vector encoding firefly luciferase, red fluorescence protein, and thymidine kinase. Alginate cell microencapsulation was performed using a modification to incorporate perfluorooctylbromide (PFOB). Bioluminescence imaging (BLI, Xenogen IVIS 2000) was acquired before and after cell encapsulation to assess *in vitro* cell viability. Rabbits received either intramuscular injection of PFOB-encapsulated TF-hMSCs in the medial thigh followed by intravenous administration of \[18F\] 9-\[4-fluoro-3-(hydroxymethy) butyl\] guanine (\[18F\]-FHBG) (n=7, 1.7±0.7 mCi), or PFOB-encapsulated TF-hMSCs that were pre-incubated with \[18F\]-FHBG (n=3, 55±2 µCi). Dynamic PET imaging (Siemens HRRT CPS Innovation) was acquired immediately or 60 min after transplantation for 30-90 min. Proton (3D GRE, TR/TE=15/5.45 ms, FOV=186x230 mm, voxel size=0.45x0.45x1.5mm) and 19F MRIs (TrueFISP, Siemens Tim Trio, TR/TE=4.1/2.0 ms, 32 averages, FOV=250x250 mm, image matrix=192x192, BW=1002 Hz/pixel, voxel size= 1.3x1.3x1.25 mm) were obtained 1-2 days after delivery. PET images were fused with 1H/19F MR to identify the location of transplanted cells. Follow-up PET imaging was repeated within 1-14 days with intravenous or ultrasound-guided intramuscular (0.7±0.3 mCi/thigh) of administration of \[18F\]-FHBG. Follow-up 19F MRIs were acquired 1-2 days after PET imaging. BLI was performed 2 weeks after delivery.

Results
=======

*In vitro* hMSC viability and transgene expression were not affected by encapsulation or \[18F\]-FHBG incubation as determined by BLI and live/dead cell staining (91±6%). All PFOB cap injections were identified on ^19^F MRI *in vivo* (Figure [1A](#F1){ref-type="fig"}). Using PET, PFOB microcapsule injection site in rabbit thigh was identified as \"hot spot\" (Figure [1B](#F1){ref-type="fig"}) and showed high concordance to the MRI \"hot spot\" (Figure [1C](#F1){ref-type="fig"}). No significant volume change of PFOB Caps was observed on ^19^F MRI over 2 weeks. BLI demonstrated viable xenogeneic TF-hMSCs in PFOB microcapsules 2 week post delivery (Figure [1D](#F1){ref-type="fig"}).

![(A) ^19^F MR image of PFOB Caps containing TF-hMSCs in a the rabbit thigh; (B) PET image of PFOB Caps in the same rabbit; (C) Fusion of ^19^F MR image (blue) and PET image (red) with anatomical ^1^H MR showing the concordance "hot spot" and the location of PFOB Caps injection site; (D) Bioluminescence imaging of the rabbit revealing highly viable encapsulated TF-hMSCs 2 weeks after delivery.](1532-429X-15-S1-M1-1){#F1}

Conclusions
===========

We demonstrate xenogeneic MSC delivery in non-immunosuppressed large animals using novel MRI-visible microencapsulation and reporter gene labeling. PFOB microencapsulation of TF-hMSCs enables cell tracking and viability assessment using clinical PET-MRI.
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